MediWound (NASDAQ:MDWD) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS

MediWound (NASDAQ:MDWD) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23, RTT News reports. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the previous year, the firm earned ($0.19) EPS.

MediWound Price Performance

NASDAQ MDWD opened at $18.28 on Thursday. The firm has a market capitalization of $197.17 million, a P/E ratio of -6.30 and a beta of 0.82. MediWound has a 1-year low of $12.78 and a 1-year high of $24.00. The business’s 50-day simple moving average is $18.15 and its 200-day simple moving average is $17.60.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of MediWound in a report on Thursday. Craig Hallum began coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 price objective for the company.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.